Cruzipain, the major cysteinyl proteinase of Trypanosoma cruzi, is expressed by all developmental forms and strains of the parasite and stimulates potent humoral and cellular immune responses during infection in both humans and mice. This information suggested that cruzipain could be used to develop an effective T. cruzi vaccine. To study whether cruzipain-specific T cells could inhibit T. cruzi intracellular replication, we generated cruzipain-reactive CD4 ؉ Th1 cell lines. These T cells produced large amounts of gamma interferon when cocultured with infected macrophages, resulting in NO production and decreased intracellular parasite replication. To study the protective effects in vivo of cruzipain-specific Th1 responses against systemic T. cruzi challenges, we immunized mice with recombinant cruzipain plus interleukin 12 (IL-12) and a neutralizing anti-IL-4 MAb. These immunized mice developed potent cruzipain-specific memory Th1 cell responses and were significantly protected against normally lethal systemic T. cruzi challenges. Although cruzipain-specific Th1 responses were associated with T. cruzi protective immunity in vitro and in vivo, adoptive transfer of cruzipain-specific Th1 cells alone did not protect BALB/c histocompatible mice, indicating that additional immune mechanisms are important for cruzipain-specific immunity. To study whether cruzipain could induce mucosal immune responses relevant for vaccine development, we prepared recombinant attenuated Salmonella enterica serovar Typhimurium vaccines expressing cruzipain. BALB/c mice immunized with salmonella expressing cruzipain were significantly protected against T. cruzi mucosal infection. Overall, these data indicate that cruzipain is an important T. cruzi vaccine candidate and that protective T. cruzi vaccines will need to induce more than CD4 ؉ Th1 cells alone.
Trypanosoma cruzi, the agent of Chagas' disease, is an important pathogen in Latin America, with an estimated 16 to 18 million people infected with the parasite (61) . About one-third of these individuals will develop clinically significant chagasic pathology, the majority with cardiac manifestations. Although an autoimmune etiology has been suggested for Chagas' disease (24) , multiple recent studies have demonstrated that in both T. cruzi-infected mice and humans, tissue pathology is correlated with the persistence of parasite infection (7, 9, 23, 29, 46, 60) . These data, along with the lack of highly efficacious treatments available for Chagas' disease, provide a strong rationale for efforts to develop a vaccine protective against T. cruzi infection.
Both CD4 ϩ and CD8 ϩ T cells are involved in T. cruzi systemic immunity, since mice lacking functional cells of either type (by genomic knockout [47, 57, 58] or by in vivo antibody depletion [3, 56, 59] ) have increased susceptibility to T. cruzi. In mice, it has been shown that CD4
ϩ Th1 responses (characterized by gamma interferon [IFN-␥] production) are associated with T. cruzi resistance, while CD4 ϩ Th2 responses (characterized by interleukin 4 production) are associated with T. cruzi susceptibility (20, 22, 28) . Studies of humans with chagasic cardiomyopathy also suggest that T cells producing IFN-␥ and IL-4 correlate with resistance and susceptibility, respectively, to cardiac disease (46) . Furthermore, we have shown previously that vaccines inducing T. cruzi-specific Th1 responses can protect mice against virulent T. cruzi challenges (21) . In addition to the induction of protective effector functions, such as microbicidal NO (38) , CD4
ϩ Th1 cells probably serve as important helper cells enhancing both CD8
ϩ -T-cell and antibody responses. As with other intracellular infections, CD8 ϩ T cells are important for recognition of parasite antigens presented by major histocompatibility complex class I molecules on the surfaces of infected cells. Lytic serum antibodies can be protective against the extracellular life stages of T. cruzi (26, 27, 31, 52) , and secretory immunoglobulin A responses may be relevant for protection against mucosal transmission from the reduviid vector (18) .
One candidate protein for vaccine development is cruzipain, the cysteinyl proteinase of T. cruzi. Cruzipain is a 57-kDa protein highly homologous with other members of the papain superfamily of proteases (12, 14, 40) , except for its C-terminal extension, which is unique to trypanosomes (5) . Although the level of cruzipain expression varies, it is produced by all life stages of the parasite (11, 49) and could be a target for immunity throughout all phases of T. cruzi infection. Surface localization of cruzipain has been reported (42, 49) , making cruzipain a potential target for lytic antibodies effective against intact extracellular parasites. Although different isoforms are found in the parasite genome (30) , highly homologous forms of cruzipain are expressed in different strains of T. cruzi (10) , indicating that cruzipain-specific immunity could be reactive with parasites from widely disparate endemic regions. Further-more, specific inhibitors of cysteinyl proteinases and cruzipainspecific antibodies have been shown to inhibit T. cruzi intracellular replication in vitro (36, 54) .
Cruzipain has been shown to be antigenic in T. cruzi-infected persons, a fact that is relevant for the development of a vaccine useful in humans. The majority of Chagas' disease patients have serum antibodies reactive with cruzipain (32, 33, 49) . In addition, cruzipain-specific T-cell lines generated from T. cruzi-infected individuals have been shown to produce IFN-␥ but not IL-4 (4), indicating that cruzipain induces human Th1 cell responses.
In this report, we demonstrate that cruzipain-specific CD4 ϩ Th1 cells can induce macrophages to produce NO and inhibit parasite replication in vitro. We also demonstrate in vivo that cruzipain-specific immunity induced by recombinant cruzipain vaccines can protect mice against virulent T. cruzi mucosal and systemic challenges.
MATERIALS AND METHODS
Organisms used. The mice used in these studies were 6-to 10-week-old BALB/c mice. The Tulahuén strain of T. cruzi was used in the experiments. Culture-derived metacyclic trypomastigotes (CMT) were generated in Grace's medium as previously described (20) . Blood form trypomastigotes (BFT) were obtained from BALB/c or SCID mice infected 2 to 3 weeks previously. Insectderived metacyclic trypomastigotes (IMT) were obtained from T. cruzi-infected Dipetalogaster maximus reduviid insects as previously described (18) .
Reagents used. The 212BH6 monoclonal antibody (MAb) specific for cruzipain (39) was provided by Julio Scharfstein (Universidade Rio de Janiero, Rio de Janeiro, Brazil). To prepare total T. cruzi lysate, CMT were washed three times with cold phosphate-buffered saline (PBS), freeze-thawed four times, and ultracentrifuged at 100,000 ϫ g for 1 h, and the supernatant was clarified by passage through 0.45-m-pore-size filters.
Purification of recombinant cruzipain. The DNA fragment encoding the mature cruzipain enzyme (amino acids 1 to 345) was amplified by PCR from a cDNA library prepared from Tulahuén trypomastigote mRNA with cruzipainspecific primers (GCGCCATGGCGCCCGCGGCAGTGGATTGG [5Ј end of the coding sequence with an NcoI site incorporated] and GCGAAGCTTCCCT CAGAGACGGCGATGACGGCT [3Ј region at the stop codon of cruzipain with a HindIII site incorporated]). NcoI-and HindIII-digested pSCREEN plasmid (Novagen, Madison, Wis.) and the cruzipain-specific PCR product were ligated and used for transformation of Escherichia coli following standard techniques (48) . The cruzipain cDNA present in this recombinant plasmid was sequenced by the dideoxy chain termination method and found to be Ͼ95% identical to the sequence published by Eakin et al. (14) . This recombinant pSCREEN-cruzipain plasmid expresses a fusion protein with the phage10 protein (T7 bacteriophage gene 10 protein) encoded by the vector at the N terminus linked to the full-length mature cruzipain sequence (amino acids 1 to 345) at the C terminus. The phage10 control and recombinant phage10/cruzipain proteins were purified from lysates of isopropyl-␤-D-thiogalactopyranoside-induced E. coli BL21(pLysS) transformed with the empty pSCREEN and pSCREEN-cruzipain plasmids, respectively, by His tag affinity chromatography. Inclusion bodies containing these proteins were pelleted by centrifugation and washed three times with 50 mM Tris-50 mM NaCl-1 mM EDTA, pH 8.0. The washed inclusion bodies were suspended in 50 mM Tris-50 mM NaCl-1 mM EDTA, pH 8.0, with 8 M urea and stirred for 4 h at room temperature. After centrifugation for 15 min at 12,000 ϫ g, the supernatants were diluted 10-fold into 20 mM Tris-300 mM NaCl, pH 10.7, and stirred for 1 h at room temperature. After the pH was adjusted to 8.0, the solutions were stirred for one more hour. Solubilized protein was filtered through 0.45-m-pore-size filters and purified over Ni-nitrilotriacetic acid agarose columns (Qiagen, San Diego, Calif.) as described by the manufacturer. Endotoxin was removed with Triton X-114 as described previously (2) . Residual Triton X-114 was removed with SM-2 beads (Bio-Rad). The endotoxin levels in the final purified proteins were Ͻ100 endotoxin units/mg, determined using Limulus amebocyte lysate (Associates of Cape Cod, Woods Hole, Mass.). Protein levels were determined using the bicinchoninic acid protein assay (Pierce, Rockford, Ill.). Both phage10 control and phage10/cruzipain final protein preparations were Ͼ95% pure as assessed by Coomassie-stained sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Western blots were probed with the 212BH6 cruzipain-specific MAb to confirm the presence of cruzipain epitopes within the phage10/cruzipain fusion protein as previously described (19) .
Generation of T-cell lines. Cruzipain-specific T-cell lines were derived from infected BALB/c mice. To bias for Th1 responses during infection, mice were injected intraperitoneally with 1 g of IL-12 daily for 18 days. On days 2, 9, and 19, these mice were also injected intraperitoneally with 1 mg of the anti-IL-4 neutralizing MAb 11B11. On day 4, the mice were infected with 20,000 IMT subcutaneously. Two months after infection, the spleens from these mice were harvested, and CD4 ϩ T cells were purified by positive magnetic selection in Mini-MACS columns (Miltenyi Biotec, Auburn, Calif.). The CD4 ϩ T cells were stimulated with 2 g of recombinant cruzipain/ml in the presence of syngeneic irradiated spleen cells as antigen-presenting cells. One week later, the cells were expanded in the presence of 10 U of IL-2/ml. This alternating schedule of antigen stimulation and IL-2 expansion was repeated biweekly.
To generate negative control ovalbumin-specific Th1 cell lines, CD4 ϩ T cells were purified from the spleen of a female D10.11 TCR transgenic mouse (provided by Lynn Dustin). CD4
ϩ T cells were stimulated with syngeneic irradiated spleen cells, 100 g of ovalbumin/ml, and 10 U of IL-12/ml to bias for Th1 responses. These cultures were then maintained by an alternating schedule of antigen stimulation and IL-2 expansion repeated biweekly. IL-12 was added during the second and third antigen stimulations to further enhance the generation of ovalbumin-specific Th1 cells.
For testing antigen specificity and cytokine profiles, T cells were studied 2 weeks after the last antigenic stimulation and 1 week after the last IL-2 expansion step. T cells (10 4 /well) were stimulated in 96-well plates with syngeneic spleen cells and titrations of phage10 control or recombinant cruzipain proteins (0 to 0.4 g/ml). After 48 h at 37°C, the supernatants were harvested for cytokine enzymelinked immunosorbent assay (ELISA) studies. Both T-cell lines produced IFN-␥, but not IL-4, in an antigen-specific, major histocompatibility complex-restricted fashion.
In vitro protection assays. Female BALB/c mice were given 100 g of concanavalin A intraperitoneally to activate peritoneal macrophages. Four days later, the peritoneal exudate macrophages (PEM) were harvested from these mice and cultured in eight-well tissue culture slide chambers (Nalge Nunc International, Naperville, Ill.) at 1.25 ϫ 10 6 cells/well in 500 l of Dulbecco's modified Eagle's medium plus 10% fetal calf serum. The PEM were allowed to adhere for at least 2 h at 37°C, washed twice with Dulbecco's modified Eagle's medium plus 2% fetal calf serum, and infected with 6.25 ϫ 10 6 CMT (a multiplicity of infection of 5). These cultures were incubated overnight at 37°C and then washed three times to remove extracellular parasites. Cruzipain-or ovalbumin-specific T cells were added at 5 ϫ 10 4 cells/well. Forty-eight hours after the addition of T cells, the supernatants were collected from these cocultures. Adherent PEM were then fixed with 1% formalin and Giemsa stained (Diff Quik; Dade International Inc., Miami, Fla.). The number of infected cells per 200 total cells and the average number of intracellular amastigotes (AMA) per infected cell were determined by microscopic examination of the stained slides. IFN-␥ and IL-4 levels in the culture supernatants were measured by ELISA as described below. NO in the supernatants was measured by a modified Greiss reaction (17, 38) . Controls included uninfected wells to confirm the antigen specificity of cytokine production and wells to which T cells were not added to determine the level of infection in the absence of any immune response. Percent inhibition of infected cells or intracellular AMA/infected cell was defined as [1 Ϫ (value with T cells/value without T cells)] ϫ 100.
Induction of cruzipain-specific Th1 responses. In order to induce cruzipainspecific immunity highly polarized toward Th1 responses in vivo, immunizations were given with IL-12 and the neutralizing anti-IL-4 MAb 11B11 as previously described (21) . Three vaccinations with phage10 or phage10/cruzipain were given at 2-week intervals. The first and second immunizations were given with IL-12 and 11B11. The third immunization included antigen alone. IL-12 (1 g) was given either subcutaneously or intraperitoneally the day before, the day of, and the day after antigen administration. The 11B11 MAb was given intraperitoneally the day before and 2 days after antigen administration. The phage10 and phage10/cruzipain antigens were given subcutaneously (25 to 50 g/dose). Four weeks after the third immunization, representative animals received a booster dose of parasite lysate, and spleen cells were harvested 3 days later for in vitro immune studies. The remaining immunized and control mice were challenged 4 to 6 weeks after the third vaccination with 5,000 to 20,000 T. cruzi BFT subcutaneously.
Proliferation assays. Draining lymph node cells (LNC) from immunized mice were incubated in 96-well tissue culture plates (4 ϫ 10 5 cells/well) at 37°C and 5% CO 2 in the presence of medium, recombinant protein, or 10 g of T. cruzi lysate/ml for 5 days. After the supernatants were harvested on the fifth day, fresh medium containing 0. In vitro stimulations and cytokine assays with freshly harvested lymphocytes. After draining LNC were harvested from immunized mice, CD4
ϩ T cells were purified by magnetic selection using Mini-MACS (Miltenyi Biotec) according to the manufacturer's instructions. CD4
ϩ T cells (1 ϫ 10 5 to 4 ϫ 10 5 /ml) were incubated in 24-well tissue culture plates in the presence of medium or antigen and irradiated syngeneic spleen cells (2 ϫ 10 6 /well). The supernatants were studied after incubation at 37°C for 4 days. IFN-␥ and IL-4 cytokine levels in the culture supernatants were measured by ELISA as previously described (20) .
Construction of a recombinant attenuated Salmonella vaccine expressing cruzipain used for mucosal immunization and challenge experiments. We used the 4550 attenuated Salmonella enterica serovar Typhimurium strain that lacks functional cya, crp, and asd gene products to produce a recombinant salmonella vaccine expressing cruzipain (41) . This salmonella vector was transformed with the empty asd ϩ complementation plasmid pYA3341 or with a recombinant pYA3341 plasmid encoding cruzipain under the control of a trc promoter. This multicopy plasmid expresses less asd functional protein than previous asd ϩ vectors, minimizing the selective disadvantage of plasmid maintenance and allowing for enhanced immunization with expressed recombinant antigens (25) . The phage10/cruzipain DNA fragment (encoding amino acids 1 to 345 of cruzipain) was amplified by PCR from the pSCREEN-cruzipain plasmid and subcloned into the pYA3341 plasmid using NcoI 5Ј and HindIII 3Ј insertion sites. Cruzipain protein expression in recombinant Salmonella transformed with this plasmid was confirmed by Western blotting. Mice were vaccinated four times intranasally with control and cruzipain-expressing salmonella cells. The mice were lightly anesthetized with ketamine-xylazine given intraperitoneally, and salmonella vaccines were administered in 10-l volumes of PBS. A total of 2 ϫ 10 6 CFU of salmonella was given for primary vaccinations, and 2 ϫ 10 7 CFU of salmonella was given for booster vaccinations. The second vaccinations were given 4 weeks after the priming doses, and the three booster vaccinations were given at 2-week intervals. One month after the final vaccinations, the mice were challenged orally with 2,000 T. cruzi IMT. Fourteen days after challenge, gastric tissues (where initial T. cruzi mucosal invasion occurs) were studied for levels of T. cruzi DNA by real-time PCR (described below), and draining gastric LNC were examined for viable T. cruzi parasites by a limiting-dilution quantitativeculture technique as previously described (18) .
Real-time PCR detection of T. cruzi in mucosal tissues. Mouse stomachs were removed by cutting the esophageal and pyloric attachments. These organs were opened along the greater curvature and flushed with sterile PBS. Gastric tissue DNA samples were purified using a commercially available QIAamp kit (Qiagen), and the total DNA concentrations were adjusted to 40 ng/l. Primers (5Ј AACCACCACGACAACCACAA 3Ј and 5Ј TGCAGGACATCTGCACAAA GTA 3Ј) predicted to specifically amplify a 65-bp fragment of cruzipain were chosen using Primer Express version 1.5a software (Applied Biosystems, Foster City, Calif.). Real-time PCRs were set up using SYBR Green PCR Master Mix (Applied Biosystems), 900 nM (each) primer, and 200 ng of sample DNA. A standard curve was generated using positive control DNA harvested from a known concentration of T. cruzi epimastigotes grown in pure culture. These reactions were run in an ABI Prism 7700 Sequence Detector (Applied Biosystems) using the following conditions: 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. Analysis was performed using Sequence Detection Systems version 1.7a software (Applied Biosystems).
RESULTS
Purification of recombinant cruzipain. Affinity chromatography on HisϫBind resin led to the purification of proteins with sizes of 33 and 84 kDa, respectively, from the pSCREEN and pSCREEN-cruzipain plasmid-transformed E. coli (Fig. 1.) . Although the predicted mass of the cruzipain fusion protein is 74 kDa, it has been reported previously that both the recombinant and native cruzipain proteins migrate with masses larger than those predicted by their amino acid sequences (34) . Recombinant cruzipain, but not the phage10 control protein, was detected in Western blots using the 212BH6 cruzipain-specific MAb as a probe (Fig. 1.) , confirming the identity of the purified product as cruzipain.
Cruzipain-specific Th1 cells protect against parasite infection in vitro. To test the hypothesis that cruzipain-specific Th1 cells can mediate protective T. cruzi immunity, we generated cruzipain-specific Th1 cell lines as described in Materials and Methods. The protection provided by these cell lines was first tested in an in vitro model. Cruzipain-specific Th1 cells were incubated with PEM that were either infected with T. cruzi or uninfected, and cytokine and NO responses were measured as described in Materials and Methods. Th1 cells specific for ovalbumin were studied in parallel experiments to control for nonspecific effects. The cruzipain-and ovalbumin-specific Tcell lines produced IFN-␥ but not IL-4 in response to soluble cruzipain or ovalbumin, respectively (data not shown), confirming that they were Th1-like T-cell lines. In the absence of T cells, culture supernatants from both infected and uninfected PEM had no detectable levels of IFN-␥ (Fig. 2a) . Ovalbuminspecific T cells produced low levels of IFN-␥ that were not different in infected and uninfected PEM cultures. However, the cruzipain-specific Th1 cells produced 344 U of IFN-␥/ml when incubated with infected PEM, a 3.9-fold increase compared with the response after incubation with uninfected PEM (Fig. 2a) . These results demonstrate that cruzipain-specific Th1 cells can respond to cruzipain in the context of intracellular T. cruzi infection. The levels of NO in these cultures were measured as well (Fig. 2b) . PEM produced only very low NO levels in the absence of T cells, and addition of the ovalbuminspecific control cells led to only minimal increases in NO production that were not different in infected and uninfected cultures. Cruzipain-specific Th1 cells did not induce uninfected PEM to produce NO above background levels seen with ovalbumin-specific T cells. However, these cruzipain-specific (Fig. 2c) . Infected macrophages cultured with ovalbumin-specific Th1 cells had similar percentages of infected cells and increased numbers of AMA per infected cell detectable after 48 h compared with infected macrophages cultured without T cells. In contrast, the cruzipain-specific Th1 cells inhibited the proportion of infected cells by 76% and reduced by 53% the average number of AMA per infected cell. Parallel cultures were set up in 24-well plates and incubated at 37°C for up to 1 week. In the absence of T cells, or in the presence of ovalbumin-specific control T cells that did not inhibit T. cruzi growth, trypomastigotes were easily detected in the supernatants by 72 h. However, in the cultures incubated with cruzipain-specific Th1 cells, trypomastigotes were never detected (data not shown). These data indicate that cruzipain-specific Th1 cells are protective against intracellular T. cruzi replication in vitro. IL-12 more effectively biases for Th1-like responses when given by the same route as antigen. To determine the most effective method for using IL-12 to induce Th1-polarized immune responses, different routes for the administration of IL-12 were compared. Two groups of mice were immunized subcutaneously with whole T. cruzi lysate three times at 2-week intervals. In each case, the first two immunizations were given with IL-12 on the day before, the day of, and the day after antigen administration, and the 11B11 IL-4-neutralizing MAb on the day before and 2 days after antigen administration. The 11B11 MAb was given intraperitoneally to both groups. The route of IL-12 administration was the only difference between these immunization groups. One group was given IL-12 intraperitoneally, and the other was given IL-12 subcutaneously. One month after the last immunization, the mice were given a booster dose of parasite lysate alone. Three days after the boost, spleen cells from these mice were harvested and stimulated in vitro with parasite lysate. IFN-␥ and IL-4 production were measured as described in Materials and Methods. IL-12 given by the same route as antigen (subcutaneously) induced more-potent IFN-␥ responses that were predominantly polarized to a Th1 type of response, based on the 10-fold up regulation of IFN-␥ production with limited IL-4 production (Fig.  3.) .
Immunization with cruzipain plus IL-12 and 11B11 induces antigen-specific Th1 cells. Groups of mice were immunized with either phage10 control or phage10/cruzipain recombinant protein as described in Materials and Methods using IL-12 and 11B11 to bias for Th1 responses. Untreated control groups were also included. One month after the last immunization, two mice/group were given a booster dose of antigen. Draining LNC were harvested from these animals 3 days later. The CD4 ϩ T cells were purified and stimulated in the presence of syngeneic, irradiated spleen cells for 3 days with or without cruzipain to ensure that the immunization induced Th1-like antigen-specific responses. Proliferative (Fig. 4a) , IFN-␥ (Fig.  4b) , IL-4 (not shown), and IL-10 (not shown) responses were measured. Immunization with cruzipain induced an antigenspecific proliferative response, with fivefold-higher incorporation of thymidine after stimulation with cruzipain than after incubation with medium alone, indicating that the immunization was successful. These cells also made increased amounts of IFN-␥ after stimulation with cruzipain compared with control cultures. However, there was no change in IL-4 or IL-10 production, with only low levels (Ͻ5 U of IL-4/ml and Ͻ2 U of IL-10/ml) of these cytokines made after stimulation with antigen. IFN-␥ production without detectable IL-4 or IL-10 production demonstrates that the immunization protocol successfully induced Th1 but not Th2 responses. The response of lymphocytes harvested from phage10-immunized mice to recombinant cruzipain was expected, since the phage10 protein is present as a fusion partner expressed with the recombinant cruzipain. Therefore, the proliferative and IFN-␥ responses induced in these mice confirm that the control group was also immunized effectively and developed antigen-specific Th1-like responses. 
Cruzipain-immunized mice respond to infection with enhanced parasite-reactive IFN-␥ responses.
Mice were immunized with phage10 control or phage10/cruzipain protein, plus IL-12 and 11B11 as described above, and then challenged with T. cruzi BFT. Three and 14 days after infection LNC were harvested from two mice per group. The CD4 ϩ T cells were purified and stimulated in vitro with either recombinant cruzipain or parasite lysate. After 3 days, culture supernatants were harvested for cytokine studies and lymphoproliferative responses were measured by thymidine incorporation. Three days after infection, the phage10-and phage10/cruzipain-immunized mice had similar proliferative responses inducible with recombinant cruzipain (Fig. 5a) . Again, since the phage10 protein is included in the recombinant cruzipain fusion protein, this result was expected. However, by 14 days after infection, a dramatic increase in this proliferative response was detected in CD4 ϩ lymphocytes harvested from the cruzipainimmunized mice but not in CD4 ϩ lymphocytes harvested from phage10-immunized mice. IFN-␥ responses after in vitro stimulation with cruzipain (Fig. 5b) and parasite lysate (Fig. 5c) were also measured. Three days after infection, CD4
ϩ T cells from cruzipain-immunized mice produced fivefold-higher levels of IFN-␥ after in vitro stimulation with cruzipain compared with CD4
ϩ T cells from phage10-immunized mice, despite the fact that similar IFN-␥ responses were detected in both groups prior to infection (Fig. 4b) . The increased IFN-␥ responses detected in cruzipain-immunized mice persisted for 14 days after infection. The CD4 ϩ T cells harvested from cruzipainimmunized mice also produced increased IFN-␥ responses after stimulation with parasite lysate 3 days postchallenge (Fig.  5c ). No such response was seen in the control CD4 ϩ T cells. Increased parasite lysate-specific IFN-␥ responses persisted in CD4 ϩ T cells from cruzipain-immunized mice 2 weeks after the T. cruzi challenge. There were no detectable differences between the two groups in IL-4 or IL-10 production. In most cases, the levels of both of these cytokines were below the limits of detection for the assays.
The immune responses induced by immunization with cruzipain are protective against lethal parasite challenge. Mice were immunized as described in Materials and Methods. Four weeks after the last immunization, these mice were challenged subcutaneously with 5,000 T. cruzi BFT. Beginning 2 weeks postchallenge and continuing until 4 weeks post challenge, individual parasitemia levels were assessed (Fig. 6a) . As early as 15 days after immunization, the parasitemias detected in the   FIG. 3 . IL-12 administered by the same route as antigen induces optimal Th1-polarized responses. Two groups of mice were immunized three times with parasite lysate. With the first two immunizations, IL-12 was given the day before, the day of, and the day after antigen administration, and IL-4-neutralizing 11B11 was given the day before and 2 days after antigen administration. The third immunization included antigen alone. Antigen was given subcutaneously (s.c.), and 11B11 was given intraperitoneally (i.p.). Group A was given IL-12 subcutaneously, and group B was given IL-12 intraperitoneally. Three days after the last immunization, LNC were harvested and stimulated in vitro with or without parasite lysate for 3 days. The supernatants were harvested and assayed for IFN-␥ and IL-4 production by ELISA. cruzipain-immunized group were significantly lower than those in the phage10-immunized and unimmunized groups (P Ͻ 0.05 by the Mann-Whitney U test). Significantly reduced parasitemias persisted in the cruzipain-immunized group throughout the remainder of the first month postchallenge. Although there were no differences among the groups in the time it took to reach peak parasitemia, there were 5.3-and 8.7-fold decreases in peak parasitemia levels in the cruzipain-immunized animals compared with the phage10-immunized and unimmunized animals, respectively. At no time point was there a significant difference in parasitemia levels between the two control groups. In a second experiment, mice were given a more virulent T. cruzi challenge, and cruzipain immunization resulted in both reduced parasitemias and significantly reduced mortality com- pared with control mice (Fig. 6b) . While all of the unimmunized mice died within 1 month of infection, 80% of the cruzipain-immunized mice survived for Ͼ10 weeks postchallenge (P Ͻ 0.05 by Fisher's exact test). Mice given IL-12 and anti-IL-4 alone were not protected against T. cruzi challenge (data not shown).
Mucosal vaccination with recombinant salmonella expressing cruzipain protects against T. cruzi mucosal infection. Recombinant attenuated S. enterica serovar Typhimurium expressing cruzipain was prepared as described in Materials and Methods. Mice were vaccinated four times intranasally. A total of 2 ϫ 10 6 CFU of salmonella was given for primary vaccination, and 2 ϫ 10 7 CFU of salmonella was given for three booster vaccinations. The second vaccination was given 4 weeks after the first dose, and the three booster vaccinations were given at 2-week intervals. One month after the last vaccination, the mice were challenged orally with T. cruzi IMT. Fourteen days after challenge, gastric tissues (at the point of initial T. cruzi mucosal invasion [18] ) were studied for levels of T. cruzi DNA by real-time PCR (Fig. 7a) , and draining gastric LNC were examined for viable T. cruzi parasites by a limitingdilution quantitative-culture technique (Fig. 7b) . Highly significant decreases in recoverable T. cruzi DNA and viable parasites were detected in mice vaccinated with recombinant salmonella expressing cruzipain compared with unvaccinated and vaccinated control mice (P Ͻ 0.05 by Student's t test). These results were reproducible in three independent experiments. Therefore, cruzipain can induce antigen-specific mucosal protection against T. cruzi infection. In addition, in preliminary experiments intranasal vaccination with salmonella expressing cruzipain was protective against subcutaneous BFT challenges (data not shown).
DISCUSSION
Because T. cruzi replicates as an intracellular pathogen in mammalian hosts, we first investigated the feasibility of a cruzipain-based vaccine by determining whether cruzipain-specific immune responses could recognize and inhibit intracellular T. cruzi parasites. This was assessed using an in vitro model of infection. CD4 ϩ Th1 cells have been shown to be protective against T. cruzi in vivo (20, 37, 43, 44) , and they can be easily produced in vitro by recurrent stimulation with soluble proteins. Therefore, we generated stable Th1 cell lines from BALB/c mice that were reactive with our purified recombinant cruzipain antigen. We generated these Th1 cells with lymphocytes harvested from infected mice to maximize the chances that the T cells would be specific for cruzipain epitopes presented by T. cruzi-infected host cells. Indeed, our cruzipainspecific Th1 cells responded to infected macrophage cultures in vitro with the production of IFN-␥, leading to the induction of NO production by infected macrophages and potent inhibition of intracellular parasite replication (Fig. 2.) . These results demonstrated that cruzipain-specific Th1 cells are relevant for the control of T. cruzi infection, supporting further study of cruzipain as a vaccine candidate for Chagas' disease.
After demonstrating that cruzipain-specific Th1 cells could be protective against T. cruzi infection in vitro, we conducted immunization experiments to determine whether cruzipainspecific immunity could protect mice in vivo. Mice were immunized with combinations of recombinant cruzipain, recombinant IL-12, and anti-IL-4 neutralizing MAb to induce highly polarized cruzipain-specific Th1 cell responses (Fig. 3 to 6 ). The optimal immunization schedule included three doses of cruzipain given subcutaneously 2 weeks apart. With the first two doses, IL-12 was given subcutaneously the day before, the day of, and the day after antigen administration. The IL-4-neutralizing antibody was administered intraperitoneally the day before and 2 days after injection of antigen. Measurements of antigen-specific immune responses present after this vaccination protocol confirmed that cruzipain-specific memory T cells with a highly polarized Th1 cytokine profile had been induced (Fig. 4.) . Furthermore, the vaccine-induced priming of FIG. 7 . A recombinant salmonella vaccine expressing cruzipain induces T. cruzi mucosal protection. Mice were vaccinated four times intranasally with recombinant salmonella expressing cruzipain (rCPSalmonella) or control salmonella transformed with the vector alone (NCSalmonella); 2 ϫ 10 6 CFU of salmonella were given for primary vaccination, and 2 ϫ 10 7 CFU of salmonella were given for three booster vaccinations. The second vaccination was given 4 weeks after the first dose, and the three booster vaccinations were given at 2-week intervals. One month after the last vaccination, the mice were challenged orally with T. cruzi IMT. Fourteen days after challenge, gastric tissues (where initial T. cruzi mucosal invasion occurs) were studied for levels of T. cruzi DNA by real-time PCR (a), and draining gastric LNC were examined for viable T. cruzi parasites by a limiting-dilution quantitative-culture technique (b). ‫,ء‬ P Ͻ 0.05 comparing the mice given salmonella expressing cruzipain with control mice by Student's t test.
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on October 1, 2017 by guest http://iai.asm.org/ these cruzipain-specific memory Th1 cells led to the development of a more rapid and potent overall Th1 response during infectious T. cruzi challenge (Fig. 5.) . However, the most important test of a vaccine is its ability to protect against disease. Mice were immunized with our cruzipain Th1 bias protocol and challenged with a lethal dose of T. cruzi BFT. Immunization with cruzipain led to significantly decreased parasitemias compared with phage10 control-immunized and unimmunized mice (Fig. 6.) . The difference in parasitemia was apparent as early as 15 days after infection and persisted for 2 weeks, with up to eightfold decreases in parasitemia. Cruzipain-immunized mice were also protected against death, with 80% of these mice surviving the parasite challenge. These results clearly indicate that cruzipain-specific immunity can protect against T. cruzi challenges in vivo.
Our data suggest that cruzipain-specific Th1 cells are likely to be important for vaccine-induced protection against T. cruzi infection. However, we have not clearly identified the mechanism(s) responsible for the protective immunity induced by our cruzipain immunization protocol. It is possible that an early production of potent IFN-␥ responses by cruzipain-specific memory Th1 cells during acute T. cruzi infection could enhance Th1 cell and inhibit Th2 cell responses specific for other parasite antigens expressed by infected cells (8, 51) . By this mechanism of secondary influence, induction of cruzipain-specific Th1 cells could increase the levels of T. cruzi resistance not only through cruzipain-specific immune responses but also by shifting the overall pattern of T helper cell development toward a Th1 profile.
To investigate the possibility that cruzipain-specific Th1 cells alone could enhance T. cruzi resistance, we performed adoptive-transfer experiments with our stable cruzipain-specific Th1 cell lines (data not shown). In multiple experiments, we injected 5 to 20 million purified cruzipain-specific Th1 cells into BALB/c histocompatible mice, but these mice were not protected against virulent challenges with T. cruzi BFT. In fact, mice given our purified cruzipain-specific Th1 cells tended to develop slightly higher parasitemias and succumbed a day or two before control mice. We observed a similar absence of protection when we adoptively transferred Th1 cells generated by recurrent stimulation with whole T. cruzi lysate. These results surprised us, because previous investigators had been able to adoptively transfer protection against virulent T. cruzi challenges with parasite-specific Th1 cell lines and clones given to naive immunocompetent mice (37, 43, 44) . However, the previous protective Th1 transfer experiments had been done in B6 mice that are relatively resistant to T. cruzi infection, and we had been working with more susceptible BALB/c mice. In preliminary experiments, we have seen that during the first week of T. cruzi infection, lymphocytes harvested from BALB/c mice with adoptively transferred parasite-specific Th1 cells develop 70-to 80-fold increases in IL-10 responses compared with infected control BALB/c mice (unpublished data). Therefore, we hypothesize that in BALB/c mice with adoptively transferred T. cruzi-specific Th1 cells, a hyperresponsive autoregulatory IL-10 response inactivates macrophages, preventing NO production and leading to uncontrolled intracellular parasite replication. We are currently testing this hypothesis.
Other possible mechanisms for the protective immunity induced by our cruzipain Th1 bias protocol could involve lymphocyte subsets other than CD4 ϩ T lymphocytes. IL-12 is known to enhance the development of CD8 ϩ cytotoxic-T-lymphocyte responses (35, 55) and, by induction of Th1 cells, leads to increased immunoglobulin G2a isotype-specific antibody responses (1). CD8
ϩ -cytotoxic-T-lymphocyte responses have been shown to be critical for resistance during primary T. cruzi infection (15, 56, 58, 62) , and antibodies inhibiting the cysteinyl proteinase activity of cruzipain could modify T. cruzi virulence (36, 54) . Therefore, either of these immune responses could be important for the protection mediated by our cruzipain Th1 bias immunization protocol. Optimal induction of protective immunity against T. cruzi may require vaccines combining CD4
ϩ -T-cell, CD8 ϩ -T-cell, and B-cell epitopes. Regardless of the mechanism(s) responsible for cruzipainspecific protective immunity achieved in our present work, these data provide the first evidence that cruzipain-based vaccines can protect against T. cruzi challenge. In addition, our studies with recombinant salmonella expressing cruzipain provide the first demonstration that a T. cruzi vaccine can induce protective mucosal immunity (Fig. 7) . Several different strategies could be used to enhance cruzipain-specific protection. The use of other adjuvants or live vaccine vectors may result in the induction of more protective mucosal and systemic T. cruzi immunity. Prime-boost combinations of subunit and live vaccines designed to optimize CD8
ϩ -T-cell responses may also increase the level of cruzipain-specific protective immunity (50) . In addition, vaccines expressing parasite epitopes derived from multiple different T. cruzi antigens may provide the best overall protection for heterogeneous populations at risk for Chagas' disease. Other previously described antigens that might be considered for use in multicomponent T. cruzi vaccines include gp72, gp90, paraflagellar rod proteins, and members of the trans-sialidase superfamily (6, 13, 15, 37, 45, 52, 53, 62) . The data presented here strongly support the inclusion of cruzipain as well in future multivalent T. cruzi vaccines.
Before any T. cruzi vaccine candidate can be used in phase I trials in humans, it will be important to complete detailed preclinical studies to ensure that the vaccine does not trigger immunopathologic mechanisms. We have not identified any toxic effects of immunizations with our recombinant cruzipain vaccines. Cruzipain-immunized mice developed protective immunity against T. cruzi challenges and lived normal life spans compared with uninfected and unimmunized mice. However, Giordanengo et al. recently reported that immunization with native cruzipain purified from parasite lysates can induce cardiac conduction abnormalities and have suggested that cruzipain-specific immunity may be important for the pathogenesis of chagasic cardiomyopathy (16) . Although these authors present data indicating that native cruzipain immunization was associated with increased cardiac myosin-specific antibody responses, it is not clear that these myosin-specific antibodies were induced by cross-reactive cruzipain epitopes and it was not shown that the myosin-specific antibodies were causally related to the induction of cardiac abnormalities. The authors studied native cruzipain purified from parasite lysates. Native cruzipain could have caused proteolytic disruption of myocytes at the site of vaccination, releasing myosin into a milieu of potent inflammatory signals stimulated by complete Freund's adjuvant and leading to a breakdown of the normal state of myosin-specific B-cell tolerance. An additional possible expla-nation for their results is that contaminants copurified from parasite lysates with the native cruzipain, but not present in our purified recombinant-cruzipain preparations, may be responsible for the induction of myosin-specific antibodies. Furthermore, even if cruzipain-specific B-cell epitopes are cross-reactive with myosin, these cross-reactive epitopes are likely to be distinct from the cruzipain T-cell epitopes involved in the induction of protective immune responses. It is of critical importance for the potential use of cruzipain in T. cruzi vaccines to explore these different possibilities.
